Inogen, Inc. (NASDAQ:INGN – Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 744,800 shares, a decrease of 9.9% from the October 31st total of 826,300 shares. Based on an average daily volume of 192,000 shares, the short-interest ratio is currently 3.9 days.
Inogen Stock Performance
Shares of NASDAQ INGN traded up $0.40 during trading on Monday, reaching $10.11. The stock had a trading volume of 192,878 shares, compared to its average volume of 327,433. The business’s 50-day moving average price is $9.52 and its 200-day moving average price is $9.66. Inogen has a fifty-two week low of $4.93 and a fifty-two week high of $13.33. The company has a market cap of $240.82 million, a P/E ratio of -4.32 and a beta of 1.04.
Hedge Funds Weigh In On Inogen
Several institutional investors have recently bought and sold shares of INGN. Meeder Asset Management Inc. acquired a new position in shares of Inogen in the second quarter worth $30,000. CWM LLC boosted its holdings in Inogen by 2,185.9% in the second quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after purchasing an additional 6,339 shares during the period. Quarry LP acquired a new position in Inogen during the 3rd quarter worth $59,000. Verition Fund Management LLC purchased a new stake in Inogen during the 3rd quarter worth about $106,000. Finally, Virtu Financial LLC acquired a new stake in Inogen in the 3rd quarter valued at about $111,000. 89.94% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
View Our Latest Stock Report on INGN
Inogen Company Profile
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Articles
- Five stocks we like better than Inogen
- Following Congress Stock Trades
- How to Master Trading Discipline: Overcome Emotional Challenges
- How to Invest in the Best Canadian StocksĀ
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- When to Sell a Stock for Profit or Loss
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.